This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/subjekt/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F12%3A00057944%21RIV13-MZ0-00023001/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F12%3A00057944%21RIV13-MZ0-00023001
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://www.biomed.cas.cz/physiolres/pdf/61/61_609.pdf
dcterms:description
Statins are the most commonly used drugs in patients with dyslipidemia. Among the patients, a significant inter-individual variability with supposed strong genetic background in statin treatment efficacy has been observed. Genome wide screenings detected variants within the CELSR2/PSRC1/SORT1, CILP2/PBX4, APOB, APOE/C1/C4, HMGCoA reductase, LDL receptor and PCSK9 genes that are among the candidates potentially modifying response to statins. Ten variants (SNPs) within these genes (rs599838, rs646776, rs16996148, rs693, rs515135, rs4420638, rs12654264, rs6511720, rs6235, rs11206510) were analyzed in 895 (46 % men, average age 60.3 +/- 13.1 years) patients with dyslipidemia treated with equipotent doses of statins % on simvastatin or atorvastatin, doses 10 or 20 mg) and selected 672 normolipidemic controls (40 % men, average age 46.5 years). Lipid parameters were available prior to the treatment and after 12 weeks of therapy. Statin treatment resulted in a significant decrease of both total cholesterol (7.00 +/- 1.53 -> 5.15 +/- 1.17 mmol/l, P<0.0001) and triglycerides (2.03 +/- 1.01 -> 4.65 +/- 1.23 mmol/l, P<0.0005). Rs599838 variant was not detected in first analyzed 284 patients. After adjustment for multiple testing, there was no significant association between individual SNPs and statin treatment efficacy. Only the rs4420638 (APOE/C1/C4 gene cluster) G allele carriers seem to show more profitable change of HDL cholesterol (P=0.007 without and P=0.06 after adjustment). Results demonstrated that, although associated with plasma TC and LDL cholesterol per se, variants within the CEL5R2/PSRC1/SORT1, CILP2/PBX4, APOB, APOE/C1/C4, HMGCoA reductase, LDL receptor and PCSK9 genes do not modify therapeutic response to statins. Statins are the most commonly used drugs in patients with dyslipidemia. Among the patients, a significant inter-individual variability with supposed strong genetic background in statin treatment efficacy has been observed. Genome wide screenings detected variants within the CELSR2/PSRC1/SORT1, CILP2/PBX4, APOB, APOE/C1/C4, HMGCoA reductase, LDL receptor and PCSK9 genes that are among the candidates potentially modifying response to statins. Ten variants (SNPs) within these genes (rs599838, rs646776, rs16996148, rs693, rs515135, rs4420638, rs12654264, rs6511720, rs6235, rs11206510) were analyzed in 895 (46 % men, average age 60.3 +/- 13.1 years) patients with dyslipidemia treated with equipotent doses of statins % on simvastatin or atorvastatin, doses 10 or 20 mg) and selected 672 normolipidemic controls (40 % men, average age 46.5 years). Lipid parameters were available prior to the treatment and after 12 weeks of therapy. Statin treatment resulted in a significant decrease of both total cholesterol (7.00 +/- 1.53 -> 5.15 +/- 1.17 mmol/l, P<0.0001) and triglycerides (2.03 +/- 1.01 -> 4.65 +/- 1.23 mmol/l, P<0.0005). Rs599838 variant was not detected in first analyzed 284 patients. After adjustment for multiple testing, there was no significant association between individual SNPs and statin treatment efficacy. Only the rs4420638 (APOE/C1/C4 gene cluster) G allele carriers seem to show more profitable change of HDL cholesterol (P=0.007 without and P=0.06 after adjustment). Results demonstrated that, although associated with plasma TC and LDL cholesterol per se, variants within the CEL5R2/PSRC1/SORT1, CILP2/PBX4, APOB, APOE/C1/C4, HMGCoA reductase, LDL receptor and PCSK9 genes do not modify therapeutic response to statins.
dcterms:title
Impact of variants within seven candidate genes on statin treatment efficacy Impact of variants within seven candidate genes on statin treatment efficacy
skos:prefLabel
Impact of variants within seven candidate genes on statin treatment efficacy Impact of variants within seven candidate genes on statin treatment efficacy
skos:notation
RIV/00023001:_____/12:00057944!RIV13-MZ0-00023001
n6:predkladatel
n12:ico%3A00023001
n3:aktivita
n18:I n18:P
n3:aktivity
I, P(NS10579)
n3:cisloPeriodika
6
n3:dodaniDat
n10:2013
n3:domaciTvurceVysledku
n9:6513832 n9:3241513 n9:4176456 n9:6873472 n9:6198325
n3:druhVysledku
n15:J
n3:duvernostUdaju
n5:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
140725
n3:idVysledku
RIV/00023001:_____/12:00057944
n3:jazykVysledku
n16:eng
n3:klicovaSlova
Polymorphisms; Genes; Efficacy; Statins
n3:klicoveSlovo
n7:Polymorphisms n7:Statins n7:Genes n7:Efficacy
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[6905AF917F2D]
n3:nazevZdroje
Physiological research
n3:obor
n17:EB
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
9
n3:projekt
n11:NS10579
n3:rokUplatneniVysledku
n10:2012
n3:svazekPeriodika
61
n3:tvurceVysledku
Ceska, R. Hubáček, Jaroslav Zlatohlavek, L. Vrablik, M. Prusikova, M. Dlouhá, Dana Rynekrová, Jitka Adámková, Věra Lánská, Věra
n3:wos
000314138600006
s:issn
0862-8408
s:numberOfPages
9